Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 14/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 12/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.71 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.71 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.71 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.69 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13322054 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL8439489 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| Hydrochloric Acid SCHEMBL8440172 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL12190816 | 0.86 | CHRNB2 (0.77) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL8305152 | 0.86 | CHRNB2 (0.77) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL14303745 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL12122170 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL12190815 | 0.84 | CHRNB2 (0.81) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL13308403 | 0.84 | CHRNB2 (0.74) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL7676161 | 0.83 | CHRNB2 (0.84) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729103-B2 | Silent desensitizers of neuronal nAChR and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8642612-B2 | Nicotinic desensitizers and methods of selecting, testing, and using them | POTOMAC PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642612-B2 | Nicotinic desensitizers and methods of selecting, testing, and using them | POTOMAC PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110269733-A1 | Silent Desensitizers of Neuronal nAChR and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2011-11-03 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010045212-A2 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INCSTATUTS (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008011484-A2 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNB2 36/4885CHRNA3 20/4885CHRNB4 26/4885 |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | CHRNA5, CHRNA2, CHRNA10 | CHRNB2 7/4885CHRNA3 10/4885CHRNB4 11/4885 |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CHRNB2 12/4885CHRNA3 6/4885CHRNB4 15/4885 |
| US-20110269733-A1 | Silent Desensitizers of Neuronal nAChR and Methods of Use Thereof | CHRNA2, CHRNA5, CHRNB2 | CHRNB2 3/4885CHRNA3 9/4885CHRNB4 5/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | CHRNB2 12/4885CHRNA3 6/4885CHRNB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.